[go: up one dir, main page]

WO2008020056A3 - Aerosolformulierung enthaltend betaagonisten und steroide - Google Patents

Aerosolformulierung enthaltend betaagonisten und steroide Download PDF

Info

Publication number
WO2008020056A3
WO2008020056A3 PCT/EP2007/058515 EP2007058515W WO2008020056A3 WO 2008020056 A3 WO2008020056 A3 WO 2008020056A3 EP 2007058515 W EP2007058515 W EP 2007058515W WO 2008020056 A3 WO2008020056 A3 WO 2008020056A3
Authority
WO
WIPO (PCT)
Prior art keywords
steroids
aerosol formulation
formulation containing
containing beta
beta agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/058515
Other languages
English (en)
French (fr)
Other versions
WO2008020056A2 (de
Inventor
Kirsten Radau
Michael Aven
Rainer Weitzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200900267A priority Critical patent/EA200900267A1/ru
Priority to AU2007285746A priority patent/AU2007285746A1/en
Priority to EP07819951A priority patent/EP2054034A2/de
Priority to BRPI0715692-8A priority patent/BRPI0715692A2/pt
Priority to CA002660480A priority patent/CA2660480A1/en
Priority to MX2009001553A priority patent/MX2009001553A/es
Priority to JP2009525029A priority patent/JP2010501021A/ja
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of WO2008020056A2 publication Critical patent/WO2008020056A2/de
Publication of WO2008020056A3 publication Critical patent/WO2008020056A3/de
Priority to NO20090410A priority patent/NO20090410L/no
Priority to IL197024A priority patent/IL197024A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die vorliegende Erfindung betrifft eine treibgasfreie Aerosolformulierung, die eine oder mehrere Verbindungen der allgemeinen Formel (1), worin die Reste R1, R2, R3 und X' die in den Ansprüchen und in der Beschreibung genannten Bedeutungen haben können, und einen weiteren Wirkstoff 2 enthält, für die Inhalation.
PCT/EP2007/058515 2006-08-18 2007-08-16 Aerosolformulierung enthaltend betaagonisten und steroide Ceased WO2008020056A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2007285746A AU2007285746A1 (en) 2006-08-18 2007-08-16 Aerosol formulation containing beta agonists and steroids
EP07819951A EP2054034A2 (de) 2006-08-18 2007-08-16 Aerosolformulierung enthaltend betaagonisten und steroide
BRPI0715692-8A BRPI0715692A2 (pt) 2006-08-18 2007-08-16 formulaÇço farmacÊutica, uso da mesma e kit de instalaÇço
CA002660480A CA2660480A1 (en) 2006-08-18 2007-08-16 Aerosol formulation for the inhalation of beta agonists
MX2009001553A MX2009001553A (es) 2006-08-18 2007-08-16 Formulacion en aerosol que contienen beta-agonistas y esteroides.
EA200900267A EA200900267A1 (ru) 2006-08-18 2007-08-16 КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ И СТЕРОИДОВ
JP2009525029A JP2010501021A (ja) 2006-08-18 2007-08-16 βアゴニストの吸入用エアロゾル製剤
NO20090410A NO20090410L (no) 2006-08-18 2009-01-28 Aerosolformuleringer for inhalaering av beta-agonister
IL197024A IL197024A0 (en) 2006-08-18 2009-02-12 Aerosol formulation for the inhalation of beta agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06119129 2006-08-18
EP06119129.2 2006-08-18
EP07101128 2007-01-25
EP07101128.2 2007-01-25

Publications (2)

Publication Number Publication Date
WO2008020056A2 WO2008020056A2 (de) 2008-02-21
WO2008020056A3 true WO2008020056A3 (de) 2008-09-12

Family

ID=39082381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/058515 Ceased WO2008020056A2 (de) 2006-08-18 2007-08-16 Aerosolformulierung enthaltend betaagonisten und steroide

Country Status (17)

Country Link
US (1) US20080041370A1 (de)
EP (1) EP2054034A2 (de)
JP (1) JP2010501021A (de)
KR (1) KR20090040922A (de)
AR (1) AR062424A1 (de)
AU (1) AU2007285746A1 (de)
BR (1) BRPI0715692A2 (de)
CA (1) CA2660480A1 (de)
CO (1) CO6150123A2 (de)
EA (1) EA200900267A1 (de)
IL (1) IL197024A0 (de)
MX (1) MX2009001553A (de)
NO (1) NO20090410L (de)
PE (1) PE20080607A1 (de)
TW (1) TW200817010A (de)
UY (1) UY30543A1 (de)
WO (1) WO2008020056A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
EP1917253B1 (de) * 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
AR089646A1 (es) 2011-08-12 2014-09-10 Boehringer Ingelheim Vetmed Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos
WO2014016548A2 (en) * 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
IN2015DN02894A (de) * 2012-12-21 2015-09-11 Boehringer Ingelheim Vetmed
MX364652B (es) 2012-12-21 2019-05-03 Boehringer Ingelheim Vetmedica Gmbh Formulacion farmaceutica que comprende ciclesonida.
US9944618B2 (en) 2013-03-14 2018-04-17 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
AU2015276310B2 (en) 2014-06-18 2020-01-16 Boehringer Ingelheim Vetmedica Gmbh Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses
US11701478B2 (en) 2015-10-09 2023-07-18 Boehringer Ingelheim International Gmbh Method for coating microstructured components
WO2021211850A1 (en) * 2020-04-16 2021-10-21 Anovent Pharmaceutical(U.S.)., Llc Inhalable formulation of a solution containing olodaterol
CN115397417A (zh) * 2020-04-16 2022-11-25 广州谷森制药有限公司 含有噻托溴铵和奥达特罗的可吸入溶液制剂
US20220031712A1 (en) * 2020-06-23 2022-02-03 Cai Gu Huang Preparation of a pharmaceutical composition of olodaterol and budesonide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (de) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Neue Benzo-Heterocyclen
WO2004045618A2 (de) * 2002-11-15 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
WO2005102349A1 (de) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
WO2005110421A2 (de) * 2004-05-14 2005-11-24 Boehringer Ingelheim International Gmbh Aerosolformulierung für die inhalation von betaagonisten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (de) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Neue Benzo-Heterocyclen
WO2004045618A2 (de) * 2002-11-15 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
WO2005102349A1 (de) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
WO2005110421A2 (de) * 2004-05-14 2005-11-24 Boehringer Ingelheim International Gmbh Aerosolformulierung für die inhalation von betaagonisten

Also Published As

Publication number Publication date
IL197024A0 (en) 2009-11-18
JP2010501021A (ja) 2010-01-14
AU2007285746A1 (en) 2008-02-21
WO2008020056A2 (de) 2008-02-21
TW200817010A (en) 2008-04-16
US20080041370A1 (en) 2008-02-21
EA200900267A1 (ru) 2009-08-28
CA2660480A1 (en) 2008-02-21
AR062424A1 (es) 2008-11-05
EP2054034A2 (de) 2009-05-06
MX2009001553A (es) 2009-04-17
NO20090410L (no) 2009-03-02
KR20090040922A (ko) 2009-04-27
PE20080607A1 (es) 2008-07-17
BRPI0715692A2 (pt) 2013-08-06
UY30543A1 (es) 2008-03-31
CO6150123A2 (es) 2010-04-20

Similar Documents

Publication Publication Date Title
WO2008020056A3 (de) Aerosolformulierung enthaltend betaagonisten und steroide
NO20080801L (no) Aerosolformulering for inhalering av beta-agonister
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
WO2007090822A3 (de) Pharmazeutische formulierung für aerosole mit zwei oder mehr wirkstoffen und mindestens einer oberflächenaktiven substanz
WO2008013838A3 (en) Pyridizinone derivatives
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
NO20090407L (no) Aerosolformulering for inhalering av beta agonister
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007141392A3 (en) Compositions comprising betulonic acid
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2009100441A3 (en) Depot formulations
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2008009379A3 (de) Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften
WO2009018909A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2006069363A3 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
WO2008112368A3 (en) Phenylalkylcarboxylic acid delivery agents
EP2702988A3 (de) Neue Zusammensetzungen und Verfahren zur Behandlung von hyperproliferativen Erkrankungen
WO2009105969A8 (zh) 埃坡霉素类似物、其药物组合物、用途及其制备方法
WO2007102127A3 (en) New amines
WO2007083060A3 (fr) Derives de chalcone a activite antimitotique
WO2007099509A3 (en) Primary amines as renin inhibitors
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
WO2005110421A3 (de) Aerosolformulierung für die inhalation von betaagonisten

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780030670.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007819951

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2660480

Country of ref document: CA

Ref document number: MX/A/2009/001553

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 197024

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009525029

Country of ref document: JP

Ref document number: 12009500326

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1285/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007285746

Country of ref document: AU

Ref document number: 200900267

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 575345

Country of ref document: NZ

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07819951

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 09028166

Country of ref document: CO

Ref document number: 1020097005574

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007285746

Country of ref document: AU

Date of ref document: 20070816

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0715692

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090218